ObjectiveTo establish a model that can quickly identify the aroma components in different parts of Nardostachys jatamansi， so as to provide a quality control basis for the market circulation and clinical use of N. jatamansi. MethodsHeadspace solid-phase microextraction-gas chromatography-mass spectrometry（HS-SPME-GC-MS） combined with Smart aroma database and National Institute of Standards and Technology（NIST） database were used to characterize the aroma components in different parts of N. jatamansi， and the aroma components were quantified according to relative response factor（RRF） and three internal standards， and the markers of aroma differences in different parts of N. jatamansi were identified by orthogonal partial least squares-discriminant analysis（OPLS-DA） and cluster thermal analysis based on variable importance in the projection（VIP） value >1 and P<0.01. The odor data of different parts of N. jatamansi were collected by Heracles Ⅱ Neo ultra-fast gas phase electronic nose， and the correlation between compound types of aroma components collected by the ultra-fast gas phase electronic nose and the detection results of HS-SPME-GC-MS was investigated by drawing odor fingerprints and odor response radargrams. Chromatographic peak information with distinguishing ability≥0.700 and peak area≥200 was selected as sensor data， and the rapid identification model of different parts of N. jatamansi was established by principal component analysis（PCA）， discriminant factor alysis（DFA）， soft independent modeling of class analogies（SIMCA） and statistical quality control analysis（SQCA）. ResultsThe HS-SPME-GC-MS results showed that there were 28 common components in the underground and aboveground parts of N. jatamansi， of which 22 could be quantified and 12 significantly different components were screened out. Among these 12 components， the contents of five components（ethyl isovalerate， 2-pentylfuran， benzyl alcohol， nonanal and glacial acetic acid，） in the aboveground part of N. jatamansi were significantly higher than those in the underground part（P<0.01）， the contents of β-ionone， patchouli alcohol， α-caryophyllene， linalyl butyrate， valencene， 1，8-cineole and p-cymene in the underground part of N. jatamansi were significantly higher than those in the aboveground part（P<0.01）. Heracles Ⅱ Neo electronic nose results showed that the PCA discrimination index of the underground and aboveground parts of N. jatamansi was 82， and the contribution rates of the principal component factors were 99.94% and 99.89% when 2 and 3 principal components were extracted， respectively. The contribution rate of the discriminant factor 1 of the DFA model constructed on the basis of PCA was 100%， the validation score of the SIMCA model for discrimination of the two parts was 99， and SQCA could clearly distinguish different parts of N. jatamansi. ConclusionHS-SPME-GC-MS can clarify the differential markers of underground and aboveground parts of N. jatamansi. The four analytical models provided by Heracles Ⅱ Neo electronic nose（PCA， DFA， SIMCA and SQCA） can realize the rapid identification of different parts of N. jatamansi. Combining the two results， it is speculated that terpenes and carboxylic acids may be the main factors contributing to the difference in aroma between the underground and aboveground parts of N. jatamansi.

The chemical constituents from the n-butanol fraction of ethanol extract of safflower (Carthamus tinctorius L.) were isolated and purified using chromatographic process including MCI Gel CHP-20, ODS, Sephadex LH-20 column chromatography, and semi-preparative HPLC method, and one alkyne and two phenylpropanoid derivants were obtained. Their structures were identified as (5R,E)-tetradecane-12-ene-8,10-diyne-1,5,14-triol (1), (E)-8-O-β-D-glucopyranosyl n-butyl cinnamate (2), and (7S,8S)-7-(4-hydroxy-3-methoxybenzene)-7-butyl-8,9-diol (3) by modern spectroscopy methods (1D NMR, 2D NMR, UV, IR and MS). 1-3 are all new compounds. Compounds 1-3 were screened for their anti-renal fibrosis activities in vitro, and none of them showed obvious effect.

Clinical practice guidelines represent the best recommendations for patient care. They are developed through systematically reviewing currently available clinical evidence and weighing the relative benefits and risks of various interventions. However, clinical practice guidelines have to go through a long translation cycle from development and revision to clinical promotion and application, facing problems such as scattered distribution, high duplication rate, and low actual utilization. At present, the clinical practice guideline information platform can directly or indirectly solve the problems related to the lengthy revision cycles, decentralized dissemination and limited application of clinical practice guidelines. Therefore, this paper systematically examines different types of clinical practice guideline information platforms and investigates their corresponding challenges and emerging trends in platform design, data integration, and practical implementation, with the aim of clarifying the current status of this field and providing valuable reference for future research on clinical practice guideline information platforms.

Most patients with differentiated thyroid cancer have a good prognosis after radioiodine-131 therapy,but a small number of patients are insensitive to radioiodine-131 therapy and even continue to develop disease.At present,some targeted drugs can improve progression-free survival in patients with radioactive iodine-refractory differentiated thyroid cancer(RAIR-DTC),such as sorafenib and levatinib,have been approved for the treatment of RAIR-DTC.However,due to the presence of primary and acquired drug resistance,drug efficacy in these patients is unsatisfactory.This review introduces the acquired drug resistance mechanism of sorafenib in the regulation of mitogen-activated protein kinase(MAPK)and phosphatidylinositol-3-kinase(PI3K)pathways and proposes related treatment strategies,in order to provide a reference for similar drug resistance mechanism of sorafenib and effective treatment of RAIR-DTC.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.

Patient experience is regarded as an important indicator of healthcare quality,and in response to the actual needs of patients,the patient experience has been enhanced through continuous innovation of healthcare models and the development of Internet healthcare services.Focusing on the implementation of patient experience enhancement action requirements,from the construction of hospital intelligent service platform,efficiency health care to reshape the new path of medical care,to create a continuity of medical service system,to build a multidisciplinary linkage"one-stop"acute and critical care medical treatment system and other aspects of public hospitals to improve the experience of the path to improve the level of medical services.It will provide a reference for comprehensively improving the level of medical services.